MAYO CLINIC

Endoquest Robotics plans to launch a clinical trial for robotic colorectal surgery at five U.S. hospitals early next year after receiving FDA's investigational device exemption. The Paradigm study will evaluate the safety and effectiveness of Endoquest’s robotic endoscopic system for removing colorectal lesions. The trial will enroll 50 patients at Brigham and Women’s Hospital, Mayo Clinic, Cleveland Clinic, Adventhealth, and HCA Healthcare. Endoquest’s robotic surgical system aims to be less invasive, potentially improving patient outcomes with less tissue trauma and scarring.

Zimmer Biomet announces FDA clearance for OsseoFit™ Stemless Shoulder System, designed for total shoulder replacement, featuring anatomically shaped implants and OsseoTi® Porous Metal Technology for bone preservation and stable fixation. Available Q1 2025.

Aaron Siri filed a petition to revoke the polio vaccine's federal approval, questioning its safety and efficacy. The vaccine, invented in 1955, eradicated polio in the U.S. and has prevented millions of cases globally. Siri seeks a double-blind trial and label changes, also targeting 13 other vaccines for aluminum content.

Targeted therapies, including KRAS, BRAF, and CLDN18.2 inhibitors, are transforming treatment for pancreatic, colorectal, lung, and gastric cancers. Experts highlight improved response rates and survival with molecular profiling-guided treatments, emphasizing the importance of biomarker expression for treatment selection and sequencing.

Zimmer Biomet received FDA clearance for the OsseoFit™ Stemless Shoulder System, designed to match natural humeral anatomy for total shoulder replacement, preserving healthy bone and integrating with modular components for patient-specific options, available Q1 2025.

Daratumumab significantly reduces risk of smoldering multiple myeloma progressing to active disease, per Mayo Clinic's AQUILA trial. At 5 years, 63.1% of daratumumab patients remained progression-free vs. 40.8% in active-monitoring group, with 93% survival rate.

The PROSPECT-Lung trial, a large multicenter study, aims to evaluate the role of immunotherapy before and after surgery in resectable non-small cell lung cancer, determining if it improves survival and cancer-free status. It seeks to answer whether perioperative immunotherapy is more effective than adjuvant therapy alone. The trial is part of the NCI's Clinical Trials Innovation Unit, aiming to simplify trials and improve their efficacy.

EndoQuest Robotics received FDA approval for human trials of its Flexible Robotic Surgical System, aiming to improve minimally invasive surgery outcomes. The PARADIGM study will involve 50 subjects at leading US healthcare facilities, starting in January. The system, initially for colon lesions, could expand to various MIS procedures.

FDA approves Mentor’s MemoryGel Enhance breast implants, offering sizes from 930cc to 1445cc for post-mastectomy and revision surgeries, addressing a need for larger reconstruction options.